AI Article Synopsis
- Tocilizumab (TCZ) is used to reduce cytokine release syndrome (CRS) in COVID-19 patients by blocking interleukin-6 (IL-6) signalling, but its side effects are not fully understood.
- A 45-year-old patient with COVID-19 developed acute hypertriglyceridaemia after receiving TCZ, despite being treated with favipiravir for respiratory issues.
- Medical professionals should be cautious of TCZ's potential negative effects on lipid levels in COVID-19 patients, which could be compounded by the impact of the disease itself on lipids.
Article Abstract
Treatment with tocilizumab (TCZ) to block interleukin-6 (IL-6) signalling is predicted to mitigate cytokine release syndrome (CRS) caused by coronavirus disease 2019 (COVID-19). However, the adverse effects of TCZ on patients with COVID-19 remain unclear. We herein report a patient with COVID-19 treated with TCZ who developed acute hypertriglyceridaemia. Despite favipiravir treatment, acute respiratory distress syndrome developed in a 45-year-old patient with COVID-19; thus, TCZ was initiated. The triglyceride levels greatly increased after TCZ administration. Physicians should consider the negative impact of TCZ on the lipid profile in patients with COVID-19, although COVID-19-induced CRS itself may be an aggravating factor.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725631 | PMC |
| http://dx.doi.org/10.2169/internalmedicine.5244-20 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!